RECURRENT FALLOPIAN TUBE CANCER
Clinical trials for RECURRENT FALLOPIAN TUBE CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CANCER trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Matched conditions: RECURRENT FALLOPIAN TUBE CANCER
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Matched conditions: RECURRENT FALLOPIAN TUBE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for ovarian cancer: targeted drug T-DXd tested after standard treatments fail
Disease control Recruiting nowThis Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein w…
Matched conditions: RECURRENT FALLOPIAN TUBE CANCER
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can ashwagandha boost chemo in ovarian cancer? new trial aims to find out
Disease control Recruiting nowThis study tests adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) for people whose ovarian cancer has returned. The goal is to find a safe dose and see if the combination helps shrink tumors or slow cancer growth. About 72 participants with recurrent ova…
Matched conditions: RECURRENT FALLOPIAN TUBE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sham Sunder Kakar • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New registry aims to learn from Real-World retreatment of gynecologic cancers
Knowledge-focused Recruiting nowThis observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …
Matched conditions: RECURRENT FALLOPIAN TUBE CANCER
Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC